Tech Company Financing Transactions
Resilience Bio Funding Round
Resilience Bio, operating out of La Jolla, secured $800 million from 8VC, Arch Venture Partners and GV.
Transaction Overview
Company Name
Announced On
11/24/2020
Transaction Type
Venture Equity
Amount
$800,000,000
Round
Series B
Investors
8VC (Lead Investor) (Drew Oetting)
Arch Venture Partners (Lead Investor) (Robert Nelsen)
GV (David Schenkein)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Enterprise IT
Mailing Address
9310 Athena Circle
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Resilience is changing the way medicine is made -- leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Patrick Yang
Chief Executive Officer
Rahul Singhvi
Chief Scientific Officer
Richard Stoner
President
Sandy Mahatme
VP - General Counsel
Ori Solomon
VP - Manufacturing
James Miller
Browse more venture capital transactions:
Prev: 11/24/2020: Chainalysis venture capital transaction
Next: 11/24/2020: Cure Hydration venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs